Baseline clinical characteristics of study patients
| Metoprolol group (n=19) | Celiprolol group (n=21) | Placebo group (n=10) | p value | |
|---|---|---|---|---|
| Age (years) | 56.1 (2.8)* † | 67.1 (2.1)* § | 61 (2.9)† § | * 0.008,† 0.28, § 0.11 |
| Range | 20 to 72 | 45 to 82 | 47 to 76 | |
| Sex | ||||
| Male | 16 | 13 | 9 | |
| Female | 3 | 8 | 1 | |
| Aetiology | ||||
| IDC | 10 | 8 | 2 | |
| ICM | 7 | 10 | 5 | |
| HTHD | 2 | 3 | 3 | |
| NYHA functional class | ||||
| II | 8 | 9 | 5 | |
| III | 11 | 10 | 5 | |
| IV | 0 | 2 | 0 | |
| Mean NYHA class | 2.6 (0.12) | 2.7 (0.15) | 2.5 (0.18) | 0.65 |
| Symptom questionnaire score | 18.1 (3.5) | 13.5 (2.7) | 7.7 (2.9) | 0.12 |
| ETT (6 min walk, feet) | 1246 (54) | 1191 (55) | 1304 (69) | 0.47 |
| Baseline blood pressure (mm Hg) | ||||
| Sitting | 114(5)/70(3) | 113(4)/71(2) | 105(6)/65(3) | 0.48/0.35 |
| Standing | 119(6)/76(3) | 114(4)/74(2) | 107(6)/68(4) | 0.37/0.2 |
| Heart rate (beats/min) | 79.3 (2.5) | 77.9 (2.8) | 79.5 (3.5) | 0.91 |
| LVEF (%) | 26.9 (3.1) | 30.2 (2.7) | 33.1 (4.0) | 0.42 |
| LVEDD (cm) | 7.2 (0.3) | 6.9 (0.3) | 6.7 (0.2) | 0.55 |
| FS (%) | 14.4 (1.3) | 15 (1.1) | 18 (1.5) | 0.19 |
| ANF (pg/ml) | 141.4 (32.9) | 193.4 (73.5) | 269.4 (187.7) | 0.64 |
| BNP (pg/ml) | 151.9 (22.8) | 166.4 (36.1) | 128.3 (24.8) | 0.73 |
| Treatment | ||||
| Frusemide dose (mg) | 85.3 (12.7) | 56.5 (8.6) | 66 (13) | 0.16 |
| ACEI (% receiving) | 16 (84%) | 15 (71%) | 10 (100%) | |
| Nitrates (% receiving) | 10 (53%) | 14 (67%) | 3 (30%) |
Values are means (SEM) unless otherwise stated.
ACEI, angiotensin converting enzyme inhibitors; ANF, atrial natriuretic factor; BNP, brain (ventricular) natriuretic peptide; ETT, exercise tolerance test; FS, fractional shortening; HTHD, hypertensive heart disease; ICM, ischaemic cardiomyopathy; IDC, idiopathic dilated cardiomyopathy; LVEDD, left ventricular end diastolic dimension; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.